Specialty Lab Services. Deep science at scale

Similar documents
Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration

Precision Biospecimen Solutions: Paving the Way to Personalized Medicine

Explore the World of End-to-End. Integrated Lab Performance

Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

Your bridge to. better medicines

DNA. Clinical Trials. Research RNA. Custom. Reports CLIA CAP GCP. Tumor Genomic Profiling Services for Clinical Trials

4/10/2017. Agenda. Overview: Biomarker Industry. + Industry Overview + Biomarker Labs Overview + Biomarker Intended Use and Challenges

Biomarker Data Management in Clinical Trials: Addressing the Challenges of the New Regulatory Landscape

Applied Protein Services

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

LAB EXPERTS AT YOUR SIDE Over twenty years of experience

leading the way in research & development

Corporate Presentation. February 2, 2018

Personalized CAR-T Immunotherapy Platform

Course Agenda. Day One

PPD LABORATORIES COMPREHENSIVE SERVICES

HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY

227 AP and >100 CDx engagements

IBBL: Introduction to Biobanks and their services

Development of Multiplex Sensitive Anti-Drug Antibody Assays for CRISPR/Cas9 Gene Therapies

Case Studies on ultra-sensitive immunoanalytics based on Imperacer (Immuno-PCR) in clinical settings. Jan Detmers, Ph.D. (Chimera Biotec GmbH)

IBBL BIOSERVICES SAMPLE ANALYSIS & QUALITY CONTROL

Antibody Discovery at Evotec

Cancer Research. Peptide Innovations in. Neo-Epitope Analysis Immunotherapy Cancer Proteomics Enzyme Profiling Epigenetics

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

bioanalytical challenge Patrick Bennett PPD Biomarker Laboratories November 2015

Using Ligang-Binding Assay Sensitivity for Improved Matrix Tolerance and Related Parameters by Tailored Sample Dilution.

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development

First Annual Biomarker Symposium Quest Diagnostics Clinical Trials

Challenges in developing Biomarker Assays for patient selection and Companion Diagnostic (CDx) Assays in early and late stage of drug development

ImmunoID NeXT. Precision Genomics for Immuno-Oncology. ImmunoID NeXT. The Universal Cancer Immunogenomics Platform

Considerations for Successful Biomarker Bioanalysis in Regulated Environment

the biomarker testing laboratory

Start With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development. Paul Docherty PhD Relationship Management

DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS. September, 2011

The In Vitro Diagnostic CRO

AT A GLANCE. inventivhealthclinical.com

Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey

OUR MISSION OUR EXPERTISE OUR SERVICES

Almac Diagnostics. NGS Panels: From Patient Selection to CDx. Dr Katarina Wikstrom Head of US Operations Almac Diagnostics

Immunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

Partnered Discovery of High-Quality Antibody Drug Candidates. Company Presentation

Advanced Therapeutic Antibody Discovery with Multiplexed Screening

Central Laboratory Services. Anatomic Pathology Histology Services

Corporate Presentation. September 6th, 2018

Engage with us on Twitter: #Molecule2Miracle

Current Best Practices in Commercial Kit Evaluation and Validation for Biomarker Assays

Immunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals

Optimising Clinical Laboratory Operations. Alan Brown SLAS Compound Management March 2017

Managing Specimen Stability for Robust Flow Cytometric Clinical Biomarker Assays

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

Diagnostics in Oncology Mark Kockx MD, PhD

Asterand Bioscience Strategic Alliances

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

FDA Perspective on the Preclinical Development of Cancer Vaccines

Successful transfer of ligand binding assays between different laboratories

PHARMACEUTICAL BIOANALYSIS BIOANALYSIS SERVICES. Bioanalytical Expertise for Large and Small Molecules

IsoFluxTM. System. The next generation of CTC Analysis is here

Roche, Roche Molecular Diagnostics and more

DIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE

Challenges in receptor occupancy determination assays by flow cytometry in drug development

How HLA tissue typing your study-cohort can make all the difference

The Right Molecules. Designed. Delivered.

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies

ABOUT GLYCOSTEM. Company Overview

Comparative Oncology Program

QPS Neuropharmacology Overview

Preanalytical Variables in Blood Collection: Impact on Precision Medicine

Pre-clinical Case Studies of Biologic Therapeutics

UNLEASH THE POWER OF PRECISION MEDICINE

Risk-based testing for anti-drug neutralizing antibodies during development of biological therapeutics

Pharmacogenetics: A SNPshot of the Future. Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001

GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)

Revised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion

Cancer ImmunoTherapy Accelerator (CITA) Dr Shalini Jadeja

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services

Interplay of Cells involved in Therapeutic Agent Immunogenicity. Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

How Targets Are Chosen. Chris Wayman 12 th April 2012

Clinical Trial Design, Approval Process and Trial Conduct

Jefferies Healthcare Conference. June 7 th, 2017

IMMUNOTOXICOLOGY: THE WHY, WHAT, WHEN, AND HOW

Start-Up and Emerging Companies Program. High quality nucleic acid products for research, diagnostics, and therapeutics

A Risk-based Approach for In Vitro Companion Diagnostics Device FDA Approval Process Associated with Therapies that have Breakthrough Designation

Topic: Genome-Environment Interactions in Inflammatory Skin Disease

Capabilities & Services

Next Generation Sequencing of HLA: Challenges and Opportunities in the era of Precision Medicine. Dr. Paul Keown, 2016

SMCxPRO Immunoassay System Sensitivity You Can Count On

THE WHITE HOUSE Office of the Vice President

REIMAGINING DRUG DEVELOPMENT:

- OMICS IN PERSONALISED MEDICINE

A Contract Research Laboratory of Excellence

Immunological Techniques in Research and Clinical Medicine. Philip L. Cohen, M.D. Chief of Rheumatology, LKSOM 10 March 2016

TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS

Assessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells

GxP Auditing, Remediation, and Staff Augmentation

Transcription:

Specialty Lab Services Deep science at scale

Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical and clinical development. Precision for Medicine understands we re innovators in delivering specialty assay solutions. We offer expertise in immunophenotyping, immune response, ligand binding, and cell-based assays, in addition to protein and gene expression assays, global specimen logistics, and biomarker data management. Across every area, Precision works collaboratively with clients to develop custom solutions. We extend those solutions into a variety of appropriate quality systems, supporting global needs and delivering on our promise of deep science at scale. We aspire to be your scientific partner Precision partners closely with our clients to support assay development and execution from initial research through global biomarker-driven pivotal trials. We start with understanding your needs efficacy, safety, mechanism of action, biomarker discovery and implementation, patient stratification, immune monitoring and then deliver a solution, whether custom assay or standard panel, with the appropriate level of qualification/validation to meet both regulatory requirements and your budget. The solutions outlined below are representative, though not exhaustive, of the assays we routinely perform. We help our clients develop biomarker signatures and support their guided trials through approval. Advanced immune monitoring solutions Precision global solutions support immune monitoring from Phase 1 to Phase 3. These assays range across multiple platforms (e.g., flow cytometry, multiplex cytokine profiling, epigenetic markers), and we process specimens in real time as required. Precision s global labs process samples from nearly any clinical site within 24 to 30 hours of draw and utilize standardized SOPs to ensure sample integrity. Using our proprietary epigenetic panels, we can even monitor T cells from PAXgene and FFPE in most cases. Assays include: Immunophenotyping via flow cytometry (up to 18 colors, research, and CLIA) ELISA (including time-resolved fluorescence, AlphaLISA) Multiplex cytokine profiling (MSD, Luminex) ELISpot (ImmunoSpot/FluoroSpot) Epigenetic markers T-cell activation Phospho flow Representative assays include: T-cell activation and proliferation T-cell polarization of naive T cells (Th1, Th2, Th17, Treg) MLR ADCC/CDC, NK cell killing Dendritic cell generation, isolation, characterization Macrophage differentiation Neutrophil migration Bioanalytical solutions Precision s scientific leadership includes world-renowned experts. We are authorities in immunogenicity, having led industry groups and supported the FDA/EMA in developing guidelines currently in use by the entire industry. Precision heads the effort to develop standards for immunogenicity assessments of novel therapeutics, such as gene therapies and CAR-Ts. Additionally, Precision works with many biosimilar developers in preparing the full package of analytical characterization to support registration. End-to-end experience from preclinical to postapproval Receptor occupancy Tetramer flow assays Our assays include: PK Gene expression PCR, qpcr, RT-qPCR, NanoString Anti-drug antibody assays (screening, confirmation, titer) Fully compliant preclinical packages via next-generation bioanalytical solutions Optimal dose and patient selection via specialty assays and translational informatics Robust data packages via advanced global patient monitoring Assays under CLIA for screening patients into trials (e.g., MDSC via flow, HAHA via ELISA) Custom assays Neutralizing antibody assays (cell based and non cell based) Binding assays via Biacore Drug-specific IgE and complement testing Preclinical Clinical Proof of Concept Pivotal Trials Precision offers exceptional scientific depth to support the development of de novo assays, with a particular specialization in cell-based assays. We work with your scientific team to understand your needs e.g., high Specialty assays to support complex molecules, such as antibody-drug conjugates, PEGylated products, and gene therapies Examples: In vitro differentiation to Th1, Th2, Th17, Treg from naïve T cells Phase 1 custom assays for oncology small molecules (phospho flow, expression) Comprehensive immunogenicity assays for small peptides, antibodies, ADCs, BiTEs, CAR-Ts, gene therapies under GLP/GCLP Integration of biomarker (IHC, gene expression, protein assays) and clinical data to support optimal dose selection Phase 1/2 custom MDSC assay via flow conducted under CLIA for patient screening Phase 3 immune monitoring for oncology, I/O, and autoimmune (flow, ELISpot, epigenetics; fresh frozen, FFPE; global logistics) content vs high throughput and then tailor an assay to meet them. 2 3

Supporting broader biomarker solutions Precision delivers all critical assay needs to support biomarker drug trials. All data are delivered from within our biomarker data management platform. Representative assays include: Whole genome sequencing Immune repertoire sequencing Circulating tumor cell profiling Cell-free DNA Immunohistochemistry FISH Substantial specialty labs, expansive global reach Precision pairs laboratory locations on both coasts of the United States with a worldwide footprint of specialty labs. Our facilities can provide rapid, standardized specialty tissue processing wherever in the world your clinical site is. Our facilities provide extensive sample management and storage services, along with state-of-the-art cell-based and molecular assay development and execution, to clients with preclinical and clinical trial needs. Processing that s as specialized as your samples Precision places an unwavering focus on ensuring the highest sample quality and viability characteristics critical for use in specialty assays. Leading biopharmaceutical companies, major academic institutions, and governments trust us and rely on our global lab infrastructure for real-time processing, delivering uniform quality for any tissue type in more than 50 countries around the world. Precision s sample processing capabilities include: Custom kit development and collection PBMC isolations, cryopreservation, characterization, and same-day or next-day processing worldwide Blood fractionation for isolation of serum, plasma, and multiple cell types DNA/RNA extraction and quantity, quality, and purity assessment of cell subsets Cell-line immortalization and expansion with >97% expansion rate Custom processing and characterization studies Standardized SOPs for laboratory services, customizable on demand Delivering specialty lab biomarker solutions at scale through every stage of development Sample Protection Samples Assays Informatics Companion Diagnostics Ensuring integrity and traceability of sample from draw to lab Globally scalable sample management solutions Assay Design and Execution Protein, molecular biology, and imaging assays Custom assays, renowned technical team, and compliant scale-up Healthy and disease state specimens for research Global specimen logistics that minimize your risk Sample logistics from global sites to Precision s local labs for processing and further testing Ongoing quality assurance of lab footprint from trial through commercialization Translational Informatics and Biometrics Novel biomarker data management platform to manage complex data, conduct translational analyses, and simplify regulatory submissions DX Development Quality and regulatory infrastructure to take biomarkers through diagnostic development and global filing Competency assessment and monitoring regularly to ensure consistency across all labs Real-time inventory tracking through our proprietary dashboard system to monitor sample locations Our 65,000-square-foot East Coast facility is ISO 9001 and ISO 13485 certified, accredited under the CAP Biorepository Accreditation Program (BAP), and CLIA registered. Our labs are also GLP and GCLP compliant. Global PBMC processing in 24 hours or less Long- or short-term storage at optimal temperatures We have labs located in strategic biotech hubs, such as the San Francisco Bay Area, to support the local needs of emerging companies. Regular quality assurance, competency assessment, and monitoring ensure we are meeting ongoing optimal standards. We deliver a solution, whether custom assay or standard panel, with the appropriate level of qualification/validation for its intended use. Precision s lab footprint covers the world. We are currently collecting samples in over 50 countries on 5 continents. 4 5

Novel approaches to managing massive biomarker data sets Today s clinical trials rely on dense, complex data generated from multiple assays often run by multiple labs. It can be challenging to efficiently manage both data and vendors to inform real-time trial decisions. Precision can help. Our unique approach combines subject matter expertise with our proprietary biomarker data management platform to streamline your efforts. We have a deep team whose wide-ranging expertise spans data science, programming, data management, and biomarkers. We are experienced in handling the full spectrum of assays in all major therapeutic areas including oncology, CNS, and auto-immune, regularly helping Sponsors address objectives such as data integration, development of biomarker signatures, patient stratification, assessment of mechanism of action, and optimal dosing. Our cloud-based biomarker data management platform supports all aspects of our services; you have access to the data throughout the study via customized reporting packages and interactive visualizations and analysis workflows. The result: You gain an orders-of-magnitude reduction in time and cost and a mitigation of major risk to interim and final study deliverables. With our approach, you gain an orders-of-magnitude reduction in time and cost and a mitigation of risk to interim and final study deliverables. A biomarker-centric data management, delivery, and collaboration platform that supports and augments our services 6 7

For more information about our specialty lab services, please contact us at info@precisionformedicine.com.